Method of treating clostridium difficile-associated diarrhea
A method of treating a disease or disorder caused by the presence of a bacterium selected from the group consisting Clostridium species, Staphylococcus species, Enterococcus species and combinations thereof comprising administering to a patient in need an effective amount of a mixture, which comprises tiacumicin B, lipiarmycin A4, and at least one of other macrocyclic compounds:
1 .- 46 . (canceled)
47 . A pharmaceutical composition comprising a compound of Formula IX (OP-1435)
48 . The pharmaceutical composition according to claim 47 further comprising a compound of Formula II (tiacumicin B)
49 . The pharmaceutical composition according to claim 48 further comprising a compound of Formula XIV (lipiarmycin A4)
50 . The pharmaceutical composition according to claim 48 further comprising at least one compound selected from
51 . A method of treating a disease or disorder caused by the presence of Clostridium difficile comprising administering to a patient in need an effective amount of the pharmaceutical composition of claim 48 .
52 . A method of treating a disease or disorder caused by the presence of Clostridium difficile comprising administering to a patient in need an effective amount of the pharmaceutical composition of claim 49 .
53 . A method of treating a disease or disorder caused by the presence of Clostridium difficile comprising administering to a patient in need an effective amount of the pharmaceutical composition of claim 50 .
54 . The method according to any of claims 51 - 53 wherein the disease is diarrhea.
55 . The method according to any of claims 51 - 53 wherein the disease is colitis.
56 . The method according to any of claims 51 - 53 wherein the disease is infectious diarrhea.
57 . The method according to any of claims 51 - 53 wherein the disease is Clostridium difficile -associated diarrhea.
58 . The method according to any of claims 51 - 53 wherein the disease is associated with the use of antibiotics or cancer chemotherapies or antiviral therapy.
59 . The method of any of claims 51 - 53 wherein the composition is administered in an amount of about 50 mg to about 1000 mg one to three times daily within three to fifteen days.
60 . The method of any of claims 51 - 53 wherein the composition is administered in an amount of about 100 mg to about 400 mg once or twice daily.
61 . The method of any of claims 51 - 53 wherein the composition is administered in an amount of about 200 mg once or twice daily.